IDH1 and central nervous system cancer: They found that these combined modalities were able to differentiate glioma grade (AUC 0.852), ATRX mutation (AUC 0.851), MGMT mutation (AUC 0.757), IDH1 mutation (AUC 0.887), and 1p19q codeletion (AUC 0.978).